Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial

Nephrology

Volumn 22, Issue 7, 2017, Pages 548-554

  Gummer, Joel ^a   Trengove, Robert ^a   Pascoe, Elaine M ^b   Badve, Sunil V ^b,c   Cass, Alan ^b,d   Clarke, Philip ^e   McDonald, Stephen P ^f   Morrish, Alicia T ^b   Pedagogos, Eugenie ^g   Perkovic, Vlado ^b,h   Reidlinger, Donna ^b   Scaria, Anish ^b   Walker, Rowan ⁱ   Vergara, Liza A ^b   Hawley, Carmel M ^b,j   Johnson, David W ^b,j   Olynyk, John K ^a,k,l   Ferrari, Paolo ^m,n  

^a MURDOCH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

ⁱ ALFRED HOSPITAL   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

^k FIONA STANLEY HOSPITAL   (Australia)

^l CURTIN UNIVERSITY   (Australia)

^m PRINCE OF WALES HOSPITAL   (Australia)

ⁿ UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

anaemia; chronic kidney disease; erythropoiesis stimulating agents; hepcidin 25; randomised controlled trial

Indexed keywords

C REACTIVE PROTEIN; ERYTHROPOIETIN; FERRITIN; HEPCIDIN; HEPCIDIN 25; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENTOXIFYLLINE; PLACEBO; TRANSFERRIN; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; BIOLOGICAL MARKER; HEMOGLOBIN; HEPCIDIN 25, HUMAN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME ASSAY; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUADRUPOLE MASS SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TISSUE OXYGENATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VASCULAR ACCESS; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; BIOMARKERS; DARBEPOETIN ALFA; DOUBLE-BLIND METHOD; DRUG RESISTANCE; ERYTHROPOIESIS; FEMALE; HEMATINICS; HEMOGLOBINS; HEPCIDINS; HUMANS; IRON; MALE; MIDDLE AGED; PENTOXIFYLLINE; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 85020834822     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12815     Document Type: Article

References (36)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987; 316: 73–8.
2. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003; 63: 1908–14.
3. Messana JM, Chuang CC, Turenne M et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am. J. Kidney Dis. 2009; 53: 503–12.
4. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Blood Purif. 2012; 33: 238–44.
5. Lopez-Gomez JM, Perez-Flores I, Jofre R et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J. Am. Soc. Nephrol. 2004; 15: 2494–501.
6. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K, Soma M. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes. Int. J. Artif. Organs 2011; 34: 16–25.
7. de Lurdes Agostinho Cabrita A, Pinho A, Malho A et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, Stages 4 and 5. Int. Urol. Nephrol. 2011; 43: 835–40.
8. Ferrari P, Weimar W, Johnson RJ, Lim WH, Tinckam KJ. Kidney paired donation: principles, protocols and programs. Nephrol. Dial. Transplant. 2015; 30: 1276–85.
9. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am. J. Kidney Dis. 2009; 53: 823–34.
10. Kuragano T, Shimonaka Y, Kida A et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am. J. Nephrol. 2010; 31: 534–40.
11. Young B, Zaritsky J. Hepcidin for clinicians. Clin. J. Am. Soc. Nephrol. 2009; 4: 1384–7.
12. Zaritsky J, Young B, Wang HJ et al. Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 1051–6.
13. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol. Dial. Transplant. 2010; 25: 848–53.
14. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin. Chem. 2011; 57: 1650–69.
15. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology. 2010; 15: 344–9.
16. Palmer SC, Navaneethan SD, Craig JC et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Int Medicine. 2010; 153: 23–33.
17. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 1077–83.
18. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 2006; 17: 1181–91.
19. Badve SV, Beller EM, Cass A et al. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst. Rev. 2013; 8: Cd006861.
20. Johnson DW, Hawley CM, Rosser B et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol. 2008; 9: 1–7.
21. Johnson DW, Pascoe EM, Badve SV et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am. J. Kidney Dis. 2015; 65: 49–57.
22. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology. 2004; 9: 223–8.
23. Gay MCL, Mullaney I, Trinder D, Olynyk JK, Trengove RD. Quantitative assay of urinary hepcidin using MALDI-TOF mass spectrometry. Analytical Methods. 2010; 2: 268–74.
24. Anderson DS, Kirchner M, Kellogg M et al. Design and validation of a high-throughput matrix-assisted laser desorption ionization time-of-flight mass spectrometry method for quantification of hepcidin in human plasma. Analyt Chem. 2011; 83: 8357–62.
25. Marton J, Farkas G, Nagy Z et al. Plasma levels of TNF and IL-6 following induction of acute pancreatitis and pentoxifylline treatment in rats. Acta Chir. Hung. 1997; 36: 223–5.
26. Graham RM, Chua AC, Herbison CE, Olynyk JK, Trinder D. Liver iron transport. World J. Gastroenterol. 2007; 13: 4725–36.
27. Chua AC, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007; 44: 413–59.
28. Muckenthaler MU. Fine tuning of hepcidin expression by positive and negative regulators. Cell Metab. 2008; 8: 1–3.
29. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am. J. Hematol. 2006; 81: 832–7.
30. Antunes SA, Vilela RQ, Vaz JD, Canziani ME. Pentoxifylline does not alter the concentration of hepcidin in chronic kidney disease patients undergoing hemodialysis. Int. J. Artif. Organs 2014; 37: 521–8.
31. Bolignano D, D'Arrigo G, Pisano A, Coppolino G. Pentoxifylline for anemia in chronic kidney disease: a systematic review and meta-analysis. PLoS One 2015; 10: e0134104.
32. Muravyov AV, Bulaeva SV, Tikhomirova IA, Zamishlayev AV, Uzikova EV, Miloradov MJ. Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment. Clin. Hemorheol. Microcirc. 2011; 49: 431–9.
33. Sotirakopoulos N, Tsitsios T, Stambolidou M et al. The red blood cell deformability in patients suffering from end stage renal failure on hemodialysis or continuous ambulatory peritoneal dialysis. Ren. Fail. 2004; 26: 179–83.
34. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N. Engl. J. Med. 1996; 334: 420–5.
35. Goicoechea M, Caramelo C, Rodriguez P et al. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Nephrol. Dial. Transplant. 2001; 16: 2188–93.
36. Kadiroglu AK, Kadiroglu ET, Sit D, Dag A, Yilmaz ME. Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif. 2006; 24: 400–4.